Zhao Chongbo

Deputy Director of the Department of Neurology; Director of the Rare Disease Center Working Group; and Vice President of Huashan Hospital. Born in April 1974, Han nationality, joined the workforce in July 2002, and joined the China Democratic National Construction Association in December 2014. He previously served as Vice President of the Jing'an Branch of Huashan Hospital, and in 2018 became Vice President of the Hongqiao Branch of Huashan Hospital. He was appointed Vice President of Huashan Hospital in January 2024. He graduated from Fudan University Shanghai Medical College with a Doctor of Clinical Medicine degree in 2002. In June 2004, he received a clinical training certificate from the Asian Neuromuscular Disease Center (National Center for Psychiatry and Neurology, Japan). From April 2006 to May 2007, he conducted postdoctoral research at the Barrow Neurological Institute in Phoenix, Arizona, USA. He is a member of the Neurology Branch of the Chinese Medical Association and the deputy head of the Neuromuscular Diseases Group; the deputy director of the Rare Neurological Diseases Committee of the China Rare Disease Alliance; a member of the Executive Committee of the Asian Oceanian Neuromuscular Society (AOMC); and the head of the leading unit of the Chinese Myasthenia Gravis Collaborative Group. His research focuses on clinical research and mechanistic exploration of rare diseases such as myasthenia gravis and neuromuscular disorders. He was among the first in China to use tacrolimus and low-dose rituximab to treat refractory generalized myasthenia gravis and created a "profile" of T-cell subsets in patients with myasthenic crisis. His team completed China's first RCT clinical trial for myasthenia gravis, led 21 multi-center clinical studies both domestically and internationally, and spearheaded the writing of three consensus statements related to the diagnosis, treatment, and management of myasthenia gravis. His team ranks second globally in the number of SCI articles published in the field of myasthenia gravis, second only to the Mayo Clinic, and fifth globally in total impact factor. He received the "Shanghai Good Doctor" award in 2024.